

This document is important and requires your immediate attention. If you are in any doubt about the contents of this document or the action you should take, you should immediately seek your own independent financial advice from your stockbroker, solicitor or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your Ordinary Shares in AfriAg Global Plc, you should forward this document, together with the accompanying Form of Proxy, immediately to the stockbroker, bank or other agent through whom the sale or transfer was effected for delivery to the purchaser or transferee.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

The Directors, whose names appear on page 2 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Directors and the Company (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

This document does not constitute an offer to issue or sell or a solicitation of any offer to subscribe for or buy ordinary shares in AfriAg Global Plc.

AFRIAG GLOBAL PLC

*(a company incorporated and registered in the Isle of Man
under the Isle of Man Companies Act 2006 with registered number 002845V)*

NOTICE OF GENERAL MEETING DISAPPLICATION OF PRE-EMPTION RIGHTS

Notice of a General Meeting to be held at the offices of Hill Dickinson LLP, 105 Jermyn Street, St. James's, London, SW1Y 6EE at 12:00 p.m. on 19 June 2019 is set out at the end of this document. Shareholders are requested to complete and return the enclosed Form of Proxy by post or by hand to Suite 3b, 38 Jermyn Street, London, SW1Y 6DN marked for attention of the company secretary, as soon as possible, but in any event so as to arrive no later than at 12:00 p.m. on 17 June 2019 whether or not they propose to be present at the General Meeting.

The distribution of this document and the Form of Proxy in jurisdictions other than the UK may be restricted by law and therefore persons into whose possession this document and/or accompanying documents come should

inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws or regulations of such jurisdictions.

This document contains forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company. Forward-looking statements are identified by the use of such terms as “believe”, “could”, “envisage”, “estimate”, “potential”, “intend”, “may”, “plan”, “will” or variations or similar expressions, or the negative thereof. The forward-looking statements contained in this document are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialise, or if underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, certain of which are beyond the Company’s control, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this document. Except as required by law, the Company undertakes no obligation to publicly release any update or revisions to the forward-looking statements contained in this document to reflect any change in events, conditions or circumstances on which any such statements are based after the time they are made.

Certain figures and percentages contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly with the total figure given.

This document will be made available on the Company’s website at www.afriaglobal.com

KEY STATISTICS

Number of Existing Ordinary Shares of the Company, including on First Admission	2,061,001,037
Number of Conditional Placing Shares	700,000,000
Issue Price	0.1 pence
Percentage of the Enlarged Share Capital represented by the Placing Shares	25.3%
Gross Proceeds of the Placing	£700,000
Approximate net Proceeds of the Placing	£630,000
Number of Ordinary Shares in issue on Second Admission	2,761,001,037

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Announcement of the Placing	on 24 May 2019
Posting of the Circular and the Form of Proxy	on 28 May 2019
Admission of the Firm Placing Shares to trading on NEX	8 a.m. on 30 May 2019
Firm Placing Shares in uncertificated form expected to be credited to accounts in CREST (uncertificated holders only)	As soon as practicable after 8 a.m. on 30 May 2019
Expected date of despatch of definitive share certificates for the Firm Placing Shares in certificated form (certificated holders only)	on 30 May 2019
Latest time and date for receipt of Forms of Proxy for the General Meeting	12 p.m. on 17 June 2019
General Meeting	12 p.m. on 19 June 2019
Announcement of the result of the General Meeting	on 19 June 2019
Second Admission of the Conditional Placing Shares to trading on NEX	8 a.m. on 25 June 2019
Conditional Placing Shares in uncertificated form expected to be credited to accounts in CREST (uncertificated holders only)	As soon as practicable after 8 a.m. on 25 June 2019
Expected date of despatch of definitive share certificates for the Conditional Placing Shares in certificated form (certificated holders only)	on 25 June 2019

*Each of the times and dates in the above timetable is subject to change. If any of the above times and/or dates change, the revised times and/or dates will be notified to Shareholders by announcement through a Regulatory Information Service. References to time in this document are to London time. The timetable above assumes that the Resolutions are passed at the

DIRECTORS AND ADVISERS

Directors	David Lenigas (<i>Executive Chairman</i>) Anthony John Samaha (<i>Finance Director</i>) Hamish Harris (<i>Non-Executive Director</i>) Donald Strang (<i>Non-Executive Director</i>)
Registered office	Quayside House 6 Hope Street Castletown Isle of Man IM9 1AS www.afriagglobal.com
Corporate adviser	Peterhouse Capital Limited New Liverpool House 15 Eldon St London EC2M 7LD
Legal advisers to the Company	Hill Dickinson LLP The Broadgate Tower 20 Primrose Street London EC2A 2EW
Registrar, Registered Agent and Administrator	Quayside Services Limited Quayside House 6 Hope Street Castletown Isle of Man IM9 1AS

LETTER FROM THE CHAIRMAN OF AFRIAG GLOBAL PLC

Directors:

David Lenigas
Anthony John Samaha
Hamish Harris
Donald Strang

Registered Office:

Quayside House
6 Hope Street, Castle Town, Isle of Man, IM9 1AS

28 May 2019

Dear Shareholder

NOTICE OF GENERAL MEETING

1 INTRODUCTION

The Company announced on 16 May 2019 that it has entered into conditional subscription agreements with Apollon Formularies Ltd (**Apollon**) to subscribe for ordinary shares in Apollon and that it would need to raise approximately £1m to subscribe for a total of 4 million shares in Apollon, representing circa 2.325 per cent. of Apollon's issued share capital.

The Company announced on 24 May 2019 that it has raised £1,000,000 by a placing of 1,000,000,000 new Ordinary Shares with existing and new institutional investors at a placing price of 0.1 pence per Placing Share.

The Placing Shares will represent approximately 25.3 per cent. of the Company's Enlarged Share Capital on Admission.

The Firm Placing Shares were placed pursuant to existing authorities granted to the Directors at the Company's annual general meeting held on 12 September 2018 and the Conditional Placing Shares are being placed conditional, *inter alia*, on the passing of the Placing Resolutions being proposed at the General Meeting. The Firm Placing is unconditional and the issue and allotment of the Firm Placing Shares shall take place at approximately 8.00 a.m. on 30 May 2019. The Conditional Placing is conditional, *inter alia*, upon Second Admission (which is expected to become effective with dealings in the Conditional Placing Shares to commence on 25 June 2019). **The Placing has not been underwritten.**

For the Conditional Placing to proceed, the Company requires Shareholders' approval to authorise the Directors to allot the Conditional Placing Shares and disapply statutory pre-emption rights in relation to the issue of the Conditional Placing Shares.

2 REASONS FOR THE PLACING

The Company has agreed with Apollon, a UK incorporated company, to (1) subscribe for 1.2 million shares in Apollon at a price per share of £0.25 representing approximately 0.71 per cent. of Apollon's issued share capital for an aggregate investment amount of £300,000; and (2) subscribe for 2.8 million shares at a price per share of £0.25 representing approximately 1.63 per cent. of Apollon's issued share capital for an aggregate investment amount of £700,000, which investment is subject to raising sufficient funds.

3 INFORMATION ON THE COMPANY

AfriAg is an investment company focussed on the acquisition of direct and indirect interest of :

- in the agriculture and logistics sectors; and
- in company's projects or products that are progressing research in and development of medicinal cannabis and its derivatives, producing or cultivating medicinal cannabis, producing or supplying products derived from or related to cannabis (including, but not limited to, hemp and cannabidiol products) and/or commercialising or marketing medicinal cannabis and its derivatives.

At present the Company holds a 40 per cent. interest in African agri-logistics group AfriAg (Pty) Ltd (**AfriAg Pty**). AfriAg Pty export a range of perishable goods from farming and fishing operations in southern Africa to Europe and Asia through Johannesburg and Cape Town international airports. The Company holds a 100 per cent. interest in AfriAg Marketing (Pty) Ltd (**AfriAg Marketing**) which was set up to focus on the export and import of perishable food products, with first orders of seafood received in September 2014.

4 INFORMATION ON APOLLON

Apollon, an international medicinal cannabis pharmaceutical company, principally conducts business through Apollon Formularies Jamaica Limited (**AFJ**), which is a government licensed medicinal cannabis company incorporated in Jamaica. Apollon, both directly and through its subsidiaries and affiliates such as AFJ, has developed a suite of proprietary, trade secret, medical cannabis strains, technology, pharmaceutical products and therapeutic applications and AFJ is licensed and approved to cultivate, process, manufacture, perform research and develop, sell and distribute within the legalized hemp and medical cannabis industry in Jamaica.

AFJ is licensed and approved to operate on the national (Federal) level in Jamaica via the following licenses and approvals: Retail (Therapeutic) License, Processing License, and Cultivation Conditional Approval pending final inspection of the cultivation facility all issued by the Cannabis Licensing Authority (CLA). AFJ has also received an approval Order for Cultivation and Clinical Trials. Together, these licenses and approvals allow for the cultivation, processing, manufacture, research and development, and retail sales of medical cannabis pharmaceuticals in Jamaica and, export internationally when the forthcoming regulations are finalized by the Jamaican government which is expected in the near future. It is expected that these regulations will allow legal export from CLA Licensed companies in Jamaica to any country where Apollon has purchase agreements and the laws of that country allow import of medical cannabis pharmaceutical products.

Along with patient care and its research and development programme, Apollon, both directly and through subsidiaries and affiliates such as AFJ, has created and obtained proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Many of these formulations were created using Apollon's proprietary artificial intelligence techniques and include:

- Apollon NAUSEA™
- Apollon PAIN™
- Apollon SLEEP™
- Apollon ANTI-INFLAMMATORY™
- Apollon SEIZURES™
- Apollon APPETITE™
- Apollon CANCER™ (APM™) – High Times Cannabis Cup 1st Place Winner.

The patient treatment side of AFJ's business is accomplished through physician managed clinical treatment wellness resorts and retail locations within Jamaica. In particular, AFJ has an arrangement with Doc's Place International, Inc. (**Doc's Place**), which operates the Global Centre of Excellence for Medical Cannabis Therapy in Negril, Jamaica. Doc's Place is an in-patient and out-patient medical cannabis wellness resort, which is used by international and Jamaican patients needing access to licensed physicians with specific expertise in medical cannabis treatment and to be prescribed medical cannabis products as has been legalised in Jamaica since April, 2015. This wellness centre is located in Negril, on the western side of Jamaica and currently has 5 in-patient treatment rooms and additional accommodations for circa 100 out-patients, with plans to expand to an 80 to 100 room in-patient treatment resort with additional accommodations for circa 500 out-patients via the purchase or rental of a second ocean front wellness resort. Any licensed physician in Jamaica, including the physicians working at Doc's Place, can write prescriptions for AFJ's medical cannabis pharmaceuticals.

The current research-driven areas of AFJ are focused upon the following:

- i. Physician supervised clinical trials for patient outcomes validation;
- ii. Accurately determined appropriate disease and patient specific formulations created using Apollon's State-of-the-Art proprietary artificial intelligence techniques;
- iii. Quality dose controlled medical cannabis oil production;

- iv. Quality controlled legal growth of medical cannabis strains;
- v. Extraction methodology, distillation, cannabinoid isolation, purification and pharmaceutical manufacturing;
- vi. Consistent dosing globally and legally through Apollon's delivery systems including one of the world's first medical cannabis 3D printer capable of precise manufacturing of Apollon's dose – controlled pharmaceutical formulations internationally' and
- vii. Global brand recognition per a consolidated strategy combined with proprietary medical cannabis strains and products.

AFJ's business objectives include the following items being accomplished in the near future:

1. Produce commercial volumes of high-grade, full-strength medical cannabis oil that will be processed at its large scale federally legal processing facility. This facility has State-of-the-Art laboratory extraction equipment with a current capacity of producing approximately 15,000 grams of the highest quality medical cannabis oil per day for retail sales in Jamaica and export to all countries where legal import is allowed. Medical cannabis oil is the primary ingredient for medical cannabis based pharmaceuticals, nutraceuticals, cosmeceuticals, foods and beverages.
2. Initially cultivate Apollon medical cannabis strains in its current greenhouse facility and expand to a 660 acre farm to be acquired or leased. The Company understands this will allow AFJ to grow approximately 1600 pounds of medical cannabis flower per acre per year. As an additional source of revenue, AFJ has established a medical cannabis collective pursuant to which it intends to allow local Jamaican farmers and other international companies to lease portions of its farm to grow medical cannabis strains on a cost plus 20% basis grown through Apollon's farming infrastructure and utilizing AFJ's licences.
3. Own and operate multiple medical wellness resorts, Doc's Place facilities, and retail locations throughout Jamaica offering Apollon's clinical trial tested, pharmaceutical products as produced by AFJ including award-winning Apollon Cancer™ used to treat cancer patients.
4. Establish and maintain a global market position.

Apollon Formularies Jamaica, Limited

Apollon holds an indirect 49% interest in the issued share capital of AFJ, a limited corporation existing under the laws of Jamaica, through an arrangement with Dr. Stephen D. Barnhill and is entitled to 95% of the net profit of the business of AFJ. Apollon has entered into an agreement with Dr Barnhill pursuant to which Dr Barnhill has agreed to assign his 49% interest (the maximum allowed under Jamaican law) of the stock in AFJ to Apollon immediately on approval of the assignment by the Cannabis Licensing Authority (CLA). In addition to such interests and rights as described above, AFJ currently has several asset purchase agreements and strategic partnerships in place to fulfil the mission of creating an all-encompassing, worldwide medical cannabis corporation that can satisfy the growing global market for legal, medical cannabis pharmaceuticals.

Doc's Place International, Inc.

Apollon has an exclusive right to acquire 90% of the stock of Doc's Place, a corporation organized and existing in the State of Georgia, USA, which includes its Wellness Center, the Global Centre of Excellence for Medical Cannabis Therapy located in Negril, Jamaica. In addition to such interest and right, there exists a leasing arrangement between AFJ and Doc's Place for AFJ to be the exclusive cannabis retail location and treatment operation located on the premises.

CBev Ventures, Inc.

Apollon also has an exclusive right to purchase the assets of CBev Ventures, Inc., a corporation organized and existing in the State of Georgia, USA ("CBev"), a beverage company that develops, markets, distributes and sells functional and craft beverages in the legal hemp and medical cannabis industry.

Roxy Industries Ltd.

Following the acquisition of CBev, Apollon will hold through CBev an exclusive right to purchase the assets of Roxy Industries Ltd., a Jamaican company that bottles, cans, and packages beverages for its customers.

5 DETAILS OF THE PLACING

The Placing has raised approximately £700,000 (before expenses) for the Company of 700,000,000 Placing

Shares at the Placing Price with existing shareholders and new institutional investors.

All of the Firm Placing Shares have been placed pursuant to existing authorities granted to the Directors at the Company's annual general meeting held on 12 September 2018 while the Conditional Placing Shares are being placed conditional, *inter alia*, on the passing of the Placing Resolutions at the General Meeting. It is expected that all of the Firm Placing Shares will be admitted to trading on NEX at 8.00 a.m. on 30 May 2019 whilst it is expected that the Conditional Placing Shares will be admitted to trading on NEX at 8.00 a.m. on 25 June 2019.

The Firm Placing is unconditional and the Firm Placing Shares shall be issued and allotted by no later than 30 May 2019.

The Conditional Placing is conditional, *inter alia*, on the passing of the Placing Resolutions.

If such conditions are not satisfied or, if applicable, waived, by the date (s) and time(s) referred to above the Conditional Placing will not proceed.

6 GENERAL MEETING

Set out at the end of this Document is the Notice of General Meeting convening the General Meeting to be held at 12p.m. on 19 June 2019 at Hill Dickinson LLP, 105 Jermyn Street, St James's, London, SW1Y 6EE, at which the Resolutions will be proposed.

Resolution 1: Disapplication of pre-emption rights

Shareholders' approval is being sought for the authority of the Board to allot the Conditional Placing Shares on a non-pre-emptive basis up to an aggregate nominal amount of £700,000 (700,000,000 new ordinary shares). This authority will expire at the earliest of the next annual general meeting of the Company or fifteen months from the date of this General Meeting.

Resolution 2: Disapplication of pre-emption rights

Shareholders' approval is being sought for the authority of the Board to allot the new ordinary shares on a non-pre-emptive basis up to an aggregate nominal amount of £1,500,000 (1,500,000,000 new ordinary shares). The authority conferred by this resolution shall expire on the conclusion of the Annual General Meeting of the Company to be held in 2020, unless such authority is renewed, varied or revoked by the Company.

7 ACTION TO BE TAKEN

A Form of Proxy is enclosed for use in connection with the General Meeting. Whether or not you intend to be present at the General Meeting, you are requested to complete, sign and return the Form of Proxy to the Company at Suite 3b, 38 Jermyn Street, London, SW1Y 6DN marked for attention of the company secretary, as soon as possible but in any event so as to arrive not later than 12:00 p.m. on 19 June 2019. The completion and return of a Form of Proxy will not preclude you from attending the meeting, or speaking and voting in person should you subsequently wish to do so.

8 RECOMMENDATION

The Directors consider that the resolutions set out in the notice of General Meeting are in the best interests of the Company and its shareholders as a whole and accordingly, unanimously recommend Shareholders to vote in favour of the resolutions to be proposed at the General Meeting.

Yours faithfully

David Lenigas

Executive Chairman

DEFINITIONS

The following definitions apply throughout this document, unless the context requires otherwise:

Admission Board	First Admission and/or Second Admission, as the context requires. the board of directors of the Company for the time being.
Company	AfriAg Global PLC, a public limited liability company incorporated and registered in the Isle of Man with company number 002845V and registered office address at Quayside House, 6 Hope Street, Castletown, Isle of Man, IM9 1AS.
Conditional Placing	the placing of the Conditional Placing Shares pursuant to the Placing.
Conditional Placing Shares	700,000,000 Ordinary Shares to be allotted and issued pursuant to the Conditional Placing.
CREST	the computerised settlement system (as defined in the CREST Regulations) operated by Euroclear which facilitates the holding and transfer of title to shares in uncertificated form.
CREST Regulations	the Uncertificated Securities Regulations 2001 (SI 2001 No. 3755) as amended.
Directors	the directors of the Company as at the date of this document whose names are listed on page 4 of this document.
Enlarged Share Capital	the issued ordinary share capital of the Company immediately following the Second Admission comprising the Existing Ordinary Shares and the Placing Shares.
Euroclear	Euroclear UK & Ireland Limited, a company incorporated in England and Wales and the operator of CREST.
Existing Ordinary Shares	the 2,061,001,037 Ordinary Shares in issue as at the date of this document.
FCA	the Financial Conduct Authority of the United Kingdom.
Firm Placing	the placing of the Firm Placing Shares pursuant to the Placing.
Firm Placing Shares	300,000,000 Ordinary Shares to be allotted and issued pursuant to the Firm Placing.
First Admission	the Admission of the Firm Placing Shares to trading on the NEX Exchange and such admission becoming effective in accordance with the NEX Rules for Companies.
FSMA	the Financial Services and Markets Act 2000, as amended.
Form of Proxy	the form of proxy for use at the General Meeting.
General Meeting	the general meeting of the Company convened pursuant to the Notice and to be held at the offices of Hill Dickinson LLP at 105 Jermyn Street, St. James's, London, SW1Y 6EE at 12.00 p.m. on 19 June 2019.
London Stock Exchange	London Stock Exchange PLC
NEX Exchange	NEX Exchange Limited, a recognised investment exchange under section 290 of FSMA.

NEX Exchange Growth Market	the primary market for unlisted securities operated by the NEX Exchange.
NEX Exchange Rules	the NEX Exchange Growth Market Rules for Issuers, which set out the admission requirements and continuing obligations of companies seeking admission to and whose shares are admitted to trading on the NEX Exchange Growth Market.
Ordinary Shares	the ordinary shares of £0.001 each in the capital of the Company.
Placing	the proposed placing of the Placing Shares at the Placing Price, conditional on Admission.
Placing Price	£0.001
Placing Resolutions	Resolution 1 as set out in the Notice to authorise the Company to allot and issue the Placing Shares.
Placing Shares	the 700,000,000 Ordinary Shares to be allotted and issued pursuant to the Placing, consisting of the Conditional Placing Shares, as the context requires.
Second Admission	the admission of the Conditional Placing Shares to trading on the NEX Exchange and such admission becoming effective in accordance with the NEX Exchange Rules.
UK or United Kingdom	the United Kingdom of Great Britain and Northern Ireland.
uncertificated	recorded on the relevant register of the share or security concerned as being held in uncertificated form in CREST and title to which, by virtue of the CREST Regulations may be transferred by means of CREST.

AFRIAG GLOBAL PLC

*(a company incorporated and registered in the Isle of Man under the Isle of Man Companies Act 2006
with registered number 002845V)*

NOTICE OF GENERAL MEETING

NOTICE IS HEREBY GIVEN that an Annual General Meeting of the Shareholders of AfriAg Global Plc (the "**Company**") will be held at the offices of Hill Dickinson LLP, 105 Jermyn Street, St. James's, London, SW1Y 6EE at 12:00 p.m. on 19 June 2019 (London time) to consider and, if thought fit, pass resolution 1 which will be proposed as a special resolution.

SPECIAL RESOLUTION

1. **THAT** the Directors of the Company be and are hereby authorised to allot and issue unissued shares in the capital of the Company for cash as if the rights of pre-emption set out in article 5,2 of the Company's articles of association did not apply to such allotment, provided that such power shall be limited to the allotment and issue of ordinary shares up to an aggregate nominal amount of £700,000 (700,000,000 new ordinary shares) and such authority expires at the earlier of the next annual general meeting of the Company or fifteen months from the date of this General Meeting.
2. **THAT** the Directors of the Company be and are hereby authorised to allot and issue unissued shares in the capital of the Company for cash as if the rights of pre-emption set out in article 5,2 of the Company's articles of association did not apply to such allotment, provided that such power shall be limited to the allotment and issue of ordinary shares up to an aggregate nominal amount of £1,500,000 (1,500,000,000 new ordinary shares). The authority conferred by this resolution shall expire on the conclusion of the Annual General Meeting of the Company to be held in 2020, unless such authority is renewed, varied or revoked by the Company.

Registered Office
Quayside House
6 Hope Street
Castletown
Isle of Man

David Lenigas
by Order of the Board
28 May 2019

Notes:

1. A member of the Company is entitled to attend and vote at the meeting and to appoint one or more proxies to attend and vote in his or her place. A proxy need not be a member of the Company.
2. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of any other joint holders. For these purposes, seniority shall be determined by the order in which the names stand in the register of members in respect of the joint holding.
3. A Form of Proxy is enclosed with this notice. Instructions for use are shown on the form. The completion and return of a Form of Proxy will not prevent a member from attending and voting in person at the meeting. In the case of a member which is a company, the Form of Proxy must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company or contained in an Electronic Communication. Any power attorney or any other authority under which the Form of Proxy is signed (or a certified copy of such power or authority) must be included with the Form of Proxy.
4. To be valid, a completed Form of Proxy together with a power of attorney or other authority (if any) under which it is executed (or a notarially certified copy of any such power or authority), must be deposited at Suite 3b, 38 Jermyn Street, London, SW1Y 6DN marked for attention company secretary, not less than 48 hours before the time set for the meeting or adjourned meeting (as the case may be).
5. Pursuant to Regulation 22 of the Uncertificated Securities Regulations 2006, only those shareholders registered in the Register of Members of the Company as at 12:00 p.m. on 17 June 2019, or in the event that the meeting is adjourned, in the Register of Members as at 12:00 p.m. on the day that is two days prior to any adjourned meeting, shall be entitled to attend or vote at the meeting in respect of the number of shares registered in their name at the relevant time. Changes to entries on the Register of Members after 12:00 p.m. on 17 June 2019 or, in the event that the meeting is adjourned, 12:00 p.m. on the day that is two days prior to the day of any adjourned meeting, shall be disregarded in determining the rights of any person to attend or vote at the meeting.
6. As at 28 May 2019 (being the last practicable date prior to the publication of this notice) the Company's issued share capital consisted of 1,761,001,037 ordinary shares of 0.1p each. Each ordinary share carries the right to vote at a general meeting of the Company, and therefore, the total number of voting rights in the Company as at 28 May 2019 was 1,761,001,037.